Abstract | BACKGROUND/AIM: MATERIALS AND METHODS:
ALCAM expression was analyzed in primary neuroblastoma specimens by immunohistochemistry on microarray sections. Histopathological and clinical data were correlated with ALCAM expression and survival analysis was performed. RESULTS: Sixty-six children were included in the study. Strong expression of ALCAM was detected in 52 (79%) of the samples. Weak expression was significantly correlated with the International Neuroblastoma Staging System (INSS) stage (p=0.024) and positive n-MYC amplification (p=0.019). Recurrence-free survival (RFS) and overall survival (OS) were significantly shorter if ALCAM was expressed weakly (p=0.032 and p=0.001). CONCLUSION: Weak ALCAM expression was significantly correlated with established markers for poor prognosis, as well as shorter RFS and OS. ALCAM might be considered as a prognostic marker for infantile neuroblastoma.
|
Authors | Robin Wachowiak, Steffi Mayer, Jussuf Kaifi, Florian Gebauer, Jakob R Izbicki, Martin Lacher, Maximilian Bockhorn, Michael Tachezy |
Journal | Anticancer research
(Anticancer Res)
Vol. 36
Issue 8
Pg. 3991-5
(Aug 2016)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 27466504
(Publication Type: Journal Article)
|
Copyright | Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. |
Chemical References |
- ALCAM protein, human
- Antigens, CD
- Biomarkers, Tumor
- Cell Adhesion Molecules, Neuronal
- Fetal Proteins
|
Topics |
- Antigens, CD
(biosynthesis, genetics)
- Biomarkers, Tumor
(biosynthesis, genetics)
- Cell Adhesion
(genetics)
- Cell Adhesion Molecules, Neuronal
(biosynthesis, genetics)
- Disease-Free Survival
- Female
- Fetal Proteins
(biosynthesis, genetics)
- Gene Expression Regulation, Neoplastic
- Humans
- Immunohistochemistry
- Infant
- Infant, Newborn
- Kaplan-Meier Estimate
- Male
- Neuroblastoma
(genetics, pathology)
- Prognosis
|